Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: The experience of the ALL-BFM 2000 trial

Klinische Padiatrie

Volumn 226, Issue 6-7, 2014, Pages 338-343

  Attarbaschi, Andishe ^a   Panzer Grumayer R ^b   Mann, G ^a   Moricke A ^c   Konig M ^b   Mecklenbrauker A ^b   Teigler Schlegel, A ^d   Bradtke, J ^d   Harbott, J ^d   Gohring G ^e   Stanulla, M ^e   Schrappe, M ^c   Zimmermann, M ^e   Haas, O A ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

iAMP21; minimale Resterkrankung; Prognose; Rezidiv

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; PEGYLATED LEVO ASPARAGINASE; PREDNISONE; RECOMBINANT ASPARAGINASE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; REPRESSOR PROTEIN; RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 21; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INTENSIFICATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; INTERMEDIATE RISK PATIENT; LONG TERM SURVIVAL; LOW RISK PATIENT; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; GENE AMPLIFICATION; GENETICS; MORTALITY; MULTICENTER STUDY; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; COHORT STUDIES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; MALE; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-ETS; RECURRENCE; REPRESSOR PROTEINS;

EID: 84923900276     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0034-1387795     Document Type: Article

References (20)

1. Attarbaschi A., Mann G., Konig M. et al. Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis. Leukemia: 2004; 18 1611 1616
2. Attarbaschi A., Mann G., Panzer-Grumayer R. et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol: 2008; 26 3046 3050
3. Attarbaschi A., Morak M., Cario G. et al. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. Br J Haematol: 2012; 158 772 777
4. Conter V., Bartram C. R., Valsecchi M. G. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood: 2010; 115 3206 3214
5. Dorge P., Meissner B., Zimmermann M. et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica: 2013; 98 428 432
6. Flohr T., Schrauder A., Cazzaniga G. et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia: 2008; 22 771 782
7. Harewood L., Robinson H., Harris R. et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia: 2003; 17 547 553
8. Harrison C. J., Moorman A. V., Schwab C. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. 2013
9. Heerema N. A., Carroll A. J., Devidas M. et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. J Clin Oncol: 2013; 31 3397 3402
10. Mitchell C., Payne J., Wade R. et al. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol: 2009; 146 424 436
11. Mitchell C. D., Richards S. M., Kinsey S. E. et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol: 2005; 129 734 745
12. Moorman A. V., Richards S. M., Robinson H. M. et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood: 2007; 109 2327 2330
13. Moorman A. V., Robinson H., Schwab C. et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol: 2013; 31 3389 3396
14. Nachman J. B., Sather H. N., Sensel M. G. et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med: 1998; 338 1663 1671
15. Pichler H., Reismuller B., Steiner M. et al. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate - a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) Study Group. Br J Haematol: 2013; 161 556 565
16. Prucker C., Attarbaschi A., Peters C. et al. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Munster study group. Leukemia: 2009; 23 1264 1269
17. Robinson H. M., Harrison C. J., Moorman A. V. et al. Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage-fusion-bridge cycle. Genes Chromosomes Cancer: 2007; 46 318 326
18. Seibel N. L., Steinherz P. G., Sather H. N. et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood: 2008; 111 2548 2555
19. van der Does-van den Berg A., Bartram C. R., Basso G. et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the BFM Family Cooperative Group. Med Pediatr Oncol: 1992; 20 497 505
20. van Dongen J. J., Seriu T., Panzer-Grumayer E. R. et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet: 1998; 352 1731 1738